Medicine
Cinqair 100 mg/10 mL injection
Cinqair 100 mg/10 mL injection is a prescription medicine containing Reslizumab for intravenous use, marketed by Teva Respiratory, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
and Stability: Refrigerate at 2 ºC to 8ºC (36°F to 46°F). Do not freeze. Do…
Key facts
- Active ingredient (INN)
- Reslizumab
- Brand
- Cinqair
- Strength
- 100 mg/10 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 10 mL
- Marketing authorisation holder
- Teva Respiratory
- Manufacturer
- Teva Respiratory
- Origin register
- US FDA, United States
- Storage
- and Stability: Refrigerate at 2 ºC to 8ºC (36°F to 46°F). Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R03DX08 Reslizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 April 2016
- Identifiers
- RxCUI 1746893, 1746898DailyMed set ID 053b9158-2a5b-48b9-bf47-5fa78a35ec33NDC 59310-610Application BLA761033
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 10 mL in 1 vial, single-use | 59310-610-31 | Teva Respiratory | 18 April 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Reslizumab is an interleukin-5 antagonist indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Reslizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ReslizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CINQAIR prescribing information (Teva Respiratory) · U.S. National Library of Medicine, DailyMed
- Cinqaero: European public assessment report (EPAR) · European Medicines Agency
Need Cinqair 100 mg/10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.